Syntekabio Presents Innovative AI Drug Discovery Cloud Platforms DeepMatcher and NEO-ARS at UKC
Global AI drug discovery and development company Syntekabio will present its innovative and efficient proprietary AI-based drug discovery cloud platforms DeepMatcher and NEO-ARS, scheduled to launch this September, on Aug. 19 at the US-Korea Conference (UKC) in Arlington, Virginia.
Latest Aithority Insights: AiThority.com to Attend The Character of AI – A Technology Ethics Conference (Virtual)
Open to all American and Korean professionals in science, engineering, technology and entrepreneurship, the industry event facilitates U.S.-Korea cooperation on recent developments and provides a cooperative networking environment for aspiring entrepreneurs to meet with high-profile business leaders and investors. The Innovative and Entrepreneurship Symposium (IES) enables participating companies with promising products and technologies to present their insights and ideas for growing cross-border business opportunities in the U.S. and Korea.
Top Artificial Intelligence Insights: Could Instances of NLP Bias Derail AI?
WHAT: The 4th Innovation and Entrepreneurship Symposium (IES) at the US-Korea Conference (UKC) 2022
WHO: Kilyoung Kim, PhD, CSO and president of Syntekabio USA, will introduce the company and present its latest technology in AI drug discovery and development at the symposium.
WHEN: Friday, Aug. 19 at 5 p.m. ET
WHERE: Hyatt Regency Crystal City, Arlington, VA
Syntekabio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people’s lives.
AI ML in Marketing: AI and Big Data Analysis Used to Find Brands’ Emotional Connection
[To share your insights with us, please write to email@example.com]